HK1119699A1 - Pyridopyrimidinone inhibitors of pi3kalpha - Google Patents

Pyridopyrimidinone inhibitors of pi3kalpha

Info

Publication number
HK1119699A1
HK1119699A1 HK08112887.3A HK08112887A HK1119699A1 HK 1119699 A1 HK1119699 A1 HK 1119699A1 HK 08112887 A HK08112887 A HK 08112887A HK 1119699 A1 HK1119699 A1 HK 1119699A1
Authority
HK
Hong Kong
Prior art keywords
pi3kalpha
pyridopyrimidinone
inhibitors
pyridopyrimidinone inhibitors
compounds
Prior art date
Application number
HK08112887.3A
Other languages
English (en)
Inventor
Tae-Gon Baik
Chris A Buhr
Katherine Lara
Sunghoon Ma
Morrison Mac
John M Nuss
Longcheng Wang
Yong Wang
Bryan K S Yeung
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HK1119699A1 publication Critical patent/HK1119699A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08112887.3A 2005-10-07 2008-11-25 Pyridopyrimidinone inhibitors of pi3kalpha HK1119699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72457105P 2005-10-07 2005-10-07
US74371906P 2006-03-23 2006-03-23
PCT/US2006/039734 WO2007044813A1 (en) 2005-10-07 2006-10-09 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα

Publications (1)

Publication Number Publication Date
HK1119699A1 true HK1119699A1 (en) 2009-03-13

Family

ID=45957942

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112887.3A HK1119699A1 (en) 2005-10-07 2008-11-25 Pyridopyrimidinone inhibitors of pi3kalpha

Country Status (20)

Country Link
US (2) US8044062B2 (xx)
EP (2) EP1940839B1 (xx)
JP (1) JP5461012B2 (xx)
KR (3) KR101492795B1 (xx)
CN (1) CN101395155A (xx)
AU (1) AU2006302078B2 (xx)
BR (1) BRPI0617159B8 (xx)
CA (1) CA2623770C (xx)
DK (1) DK1940839T3 (xx)
EA (1) EA016945B1 (xx)
ES (1) ES2432046T3 (xx)
GE (1) GEP20115304B (xx)
HK (1) HK1119699A1 (xx)
HR (1) HRP20130902T1 (xx)
IL (1) IL190292A (xx)
NO (1) NO343136B1 (xx)
NZ (2) NZ594628A (xx)
PL (1) PL1940839T3 (xx)
RS (1) RS52953B (xx)
WO (1) WO2007044813A1 (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0114829A (pt) 2000-10-23 2003-09-23 Smithkline Beecham Corp Novos compostos
TWI389690B (zh) * 2005-03-25 2013-03-21 Glaxo Group Ltd 新穎化合物（一）
EA024305B1 (ru) * 2005-10-07 2016-09-30 Экселиксис, Инк. Ингибиторы фосфатидилинозит-3-киназы и их применение
ES2432046T3 (es) * 2005-10-07 2013-11-29 Exelixis, Inc. Piridopirimidinonas inhibidoras de PI3Kalfa
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
US20100075947A1 (en) * 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
EA016388B1 (ru) 2006-09-15 2012-04-30 Пфайзер Продактс Инк. Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
MY150697A (en) * 2007-04-10 2014-02-28 Exelixis Inc Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
MY150747A (en) * 2007-04-11 2014-02-28 Exelixis Inc Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
CA2683784A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
ES2438998T3 (es) * 2007-04-11 2014-01-21 Exelixis, Inc. Terapias combinadas que comprenden un inhibidor de quinaxolina de PI3K alfa para utilizar en el tratamiento del cáncer
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
JP2010111702A (ja) * 2009-02-16 2010-05-20 Tetsuya Nishio 複素環化合物、その製造法および用途
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
SG10201500895XA (en) 2009-11-05 2015-04-29 Rhizen Pharmaceuticals Sa Chromen-4-one Derivatives As Kinase Modulators
AR080643A1 (es) 2010-02-03 2012-04-25 Signal Pharm Llc Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
CA2807498C (en) * 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
MX2013005819A (es) * 2010-11-24 2013-08-27 Exelixis Inc Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
CA2832309A1 (en) * 2011-04-08 2013-03-28 David Campbell 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
CA2834282A1 (en) * 2011-04-29 2012-11-01 Exelixis, Inc. Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
CN107337659A (zh) 2011-05-04 2017-11-10 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX2014001246A (es) 2011-08-03 2014-06-11 Signal Pharm Llc Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
CA2848724A1 (en) 2011-09-14 2013-03-21 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
SG11201401961UA (en) 2011-11-01 2014-05-29 Exelixis Inc N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013115884A2 (en) 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
CN104334192A (zh) * 2012-04-06 2015-02-04 赛诺菲 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
HUE034591T2 (en) 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S A Selective PI3K delta inhibitors
WO2014058947A1 (en) 2012-10-12 2014-04-17 Sanofi Compositions and methods for treating cancer using pi3k inhibitor and anti-cd19 maytansinoid immunoconjugate
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
TW201521792A (zh) * 2013-03-05 2015-06-16 Sanofi Sa ＰＩ３Ｋα抑制劑之錠劑調配物
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
BR112019002610A2 (pt) * 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
IL278701B2 (en) 2018-05-21 2024-09-01 Nerviano Medical Sciences Srl Heterofused pyridones and their use as IDH inhibitors
PT3813946T (pt) 2018-06-15 2024-07-10 Janssen Pharmaceutica Nv Análogos da rapamicina e suas utilizações
EP4055015A1 (en) 2019-11-08 2022-09-14 Nerviano Medical Sciences S.r.l. Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
CA3231246A1 (en) * 2021-09-10 2023-03-16 Alessandro Boezio Pi3k-alpha inhibitors and methods of use thereof
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4117131A (en) * 1976-12-07 1978-09-26 Warner-Lambert Company Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH0827122A (ja) * 1994-07-15 1996-01-30 Kureha Chem Ind Co Ltd ２−（ベンジルオキシ）（フェノキシ）ピリミジン誘導体、その製造方法及び除草剤
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
ES2301194T3 (es) * 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
KR20020070520A (ko) 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
PL358271A1 (en) 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
CN101001857B (zh) * 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
JP4603268B2 (ja) 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
JP2005530759A (ja) 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド Ｃ型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
EP1624900A4 (en) 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
RU2317296C2 (ru) * 2003-07-11 2008-02-20 Уорнер-Ламберт Компани Ллс Изетионатная соль селективного ингибитора cdk4
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
ATE373659T1 (de) 2004-05-04 2007-10-15 Warner Lambert Co Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
EP1786817A1 (de) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinone als plk (polo like kinase) inhibitoren
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EA024305B1 (ru) * 2005-10-07 2016-09-30 Экселиксис, Инк. Ингибиторы фосфатидилинозит-3-киназы и их применение
ES2432046T3 (es) * 2005-10-07 2013-11-29 Exelixis, Inc. Piridopirimidinonas inhibidoras de PI3Kalfa
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
US20100075947A1 (en) * 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
NZ576234A (en) * 2006-11-06 2011-06-30 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
MY150697A (en) * 2007-04-10 2014-02-28 Exelixis Inc Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
CA2683784A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
ES2438998T3 (es) * 2007-04-11 2014-01-21 Exelixis, Inc. Terapias combinadas que comprenden un inhibidor de quinaxolina de PI3K alfa para utilizar en el tratamiento del cáncer
MY150747A (en) * 2007-04-11 2014-02-28 Exelixis Inc Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
AR080151A1 (es) * 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia

Also Published As

Publication number Publication date
BRPI0617159B8 (pt) 2021-05-25
KR20080056195A (ko) 2008-06-20
CA2623770C (en) 2014-05-27
US20090270430A1 (en) 2009-10-29
US8044062B2 (en) 2011-10-25
CN101395155A (zh) 2009-03-25
NZ594628A (en) 2013-04-26
PL1940839T3 (pl) 2013-12-31
AU2006302078B2 (en) 2012-11-22
EA200800760A1 (ru) 2008-08-29
EP2322523A1 (en) 2011-05-18
EP1940839B1 (en) 2013-07-31
EP1940839A1 (en) 2008-07-09
WO2007044813A1 (en) 2007-04-19
JP5461012B2 (ja) 2014-04-02
EP2322523B1 (en) 2019-01-02
KR101538412B1 (ko) 2015-07-22
HRP20130902T1 (hr) 2013-11-08
ES2432046T3 (es) 2013-11-29
AU2006302078A1 (en) 2007-04-19
NO343136B1 (no) 2018-11-19
KR101492795B1 (ko) 2015-02-13
KR20140105621A (ko) 2014-09-01
JP2009511504A (ja) 2009-03-19
US20110237608A1 (en) 2011-09-29
KR20130140145A (ko) 2013-12-23
NZ566903A (en) 2011-09-30
IL190292A (en) 2017-01-31
BRPI0617159A2 (pt) 2015-01-06
BRPI0617159B1 (pt) 2021-04-13
EA016945B1 (ru) 2012-08-30
IL190292A0 (en) 2009-09-22
NO20082090L (no) 2008-05-20
DK1940839T3 (da) 2013-10-14
GEP20115304B (en) 2011-10-10
RS52953B (en) 2014-02-28
CA2623770A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
TW200728307A (en) Novel spirochromanone derivatives
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
TW200734311A (en) New compounds
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
TW200738651A (en) Cyclohexyl sulfonamide derivatives
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
TW200637817A (en) 5-aminoindole derivatives
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
NO20080033L (no) Kinolinderivater som NK3-antagonister
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives